MHC II (HLA-DRA)(IPO-10), CF640R conjugate, 0.1mg/mL [26628-22-8]

Biotium

MHC II (HLA-DRA)(IPO-10), CF640R conjugate, 0.1mg/mL

9

Research Use Only

Monoclonal

IPO-10

0.1 mg/ml

Other Conjugate

HLA-DRA

major histocompatibility complex, class II, DR alpha

histocompatibility antigen HLA-DR alpha; HLA class II histocompatibility antigen, DR alpha chain; HLA-DRA1; MHC class II antigen DRA

Mouse

IgG3

HLA class II histocompatibility antigen, DR alpha chain

MAb IPO-10 defines the antigen that appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkins disease cases a significant percentage of affected lymph node cells were detected. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Animal

Bovine, Human, Monkey, Mouse

2°C to 8°C

12352203